

**An Important Message from
The Texas Health and Human Services Commission (HHSC)**

Clinical Criteria Update for Orkambi Effective November 9

Background:

HHSC will update the approval clinical prior authorization criteria for Orkambi, a Cystic Fibrosis treatment agent. The treatment age of children who have two F508del mutations will be expanded in accordance with recent Food and Drug Administration (FDA) indications.

Key Details:

Beginning on **November 9, 2022**, HHSC will implement clinical prior authorization criteria updates for Orkambi (lumacaftor/ivacaftor). The treatment age for Orkambi will be expanded to ages 1-2 years for children with cystic fibrosis who have two F508del mutations. The prior authorization criteria guide for Orkambi can be found within the Cystic Fibrosis Agents prior authorization criteria guide.

For those MCOs who have adopted the optional Orkambi clinical prior authorization, updates are required to be implemented no later than November 9, 2022.